5-Fluoro-2-methyl-3-nitrobenzoic Acid: A Vital Intermediate for Pharmaceutical Innovation

Discover the critical role of 5-Fluoro-2-methyl-3-nitrobenzoic acid as a high-purity intermediate in the synthesis of advanced pharmaceuticals, particularly in the development of life-saving anti-cancer agents. As a leading manufacturer and supplier in China, we provide this essential building block for your research and production needs.

Get a Quote & Sample

Advantages of Sourcing Our Pharmaceutical Intermediates

Exceptional Purity for Critical Applications

Our 5-Fluoro-2-methyl-3-nitrobenzoic acid boasts a minimum purity of 98.0%, making it ideal for complex pharmaceutical synthesis where impurity control is paramount. This ensures the efficacy and safety of your final API.

Strategic Intermediate for Anti-Cancer Drugs

As a key intermediate for Rucaparib, this compound plays a vital role in the development of advanced cancer treatments. By choosing us as your supplier, you secure a critical component for therapeutic innovation.

Guaranteed Supply Chain Stability

Operating as a manufacturer and supplier in China, we offer robust production capabilities and a stable supply chain. When you need to buy this intermediate, we ensure timely delivery and competitive pricing for your ongoing projects.

Diverse Applications in Pharmaceutical Synthesis

Rucaparib Intermediate

The primary application is as a crucial intermediate in the synthesis of Rucaparib, a PARP inhibitor used in the treatment of certain types of cancer. This highlights its significance in the oncology sector.

API Synthesis

Beyond Rucaparib, this compound serves as a versatile building block for the synthesis of various Active Pharmaceutical Ingredients (APIs), offering broad utility in drug discovery and development.

Advanced Organic Synthesis

Its specific chemical structure makes it valuable in advanced organic synthesis, enabling researchers and manufacturers to create complex molecules with targeted functionalities.

Research and Development

Available for R&D purposes, this intermediate supports the exploration of new synthetic pathways and the development of novel therapeutic agents by research institutions and pharmaceutical companies.